Mon, Mar 2, 2015, 6:44 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Fonar Corp. Message Board

tfitz71 42 posts  |  Last Activity: Feb 19, 2015 2:59 PM Member since: Jun 27, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tfitz71 tfitz71 Feb 19, 2015 2:59 PM Flag

    I believe that the Company is steadfastly committed to full disclosure of any and all material events.

    Sentiment: Strong Buy

  • tfitz71 tfitz71 Feb 18, 2015 12:09 PM Flag

    Actually, the Form 8-K/A was filed on Feb. 3, 2012. Item 5.02: "It should be noted that the positions taken by Mr. Dempsey with respect to the elements of this current report are contrary to the facts as disclosed. He (i) joined in the unanimous approval of the prior minutes, (ii) was advised by the Audit Committee Chairman that the independent auditors of the Company had approved the financial disclosure position, and (iii) tendered his resignation and left the Board Meeting during discussions prior to any action being taken with respect to the Board of Directors of our subsidiary."

    Sentiment: Strong Buy

  • tfitz71 tfitz71 Feb 18, 2015 11:58 AM Flag

    See Form 8-K/A Jan. 24, 2012:
    "Mr. Dempsey alleges that insufficient information regarding Board meetings and minutes reflecting those meetings had been circulated to the Directors prior to Board meetings. In fact, as a policy and in reality, draft minutes of the prior Board Meeting and an agenda are circulated to the members of the Board in advance of the Board meeting for review and comment. Prior minutes are presented to the Board for approval at the onset of each meeting. Mr. Dempsey actually joined the unanimous vote of the Board on January 24, 2012 in approving the last minutes prior to submitting his resignation. He also has approved all prior minutes during his tenure. As to allegations of potential financial reporting irregularities, the question raised was promptly put before the independent Audit Committee. Their preliminary determination that all reporting had been in accordance with all applicable rules and regulations was delivered to the Board at the January 24 meeting only after discussions with the Independent Auditor for the Company. Notwithstanding that preliminary
    determination, the Audit Committee confirmed at the meeting to all directors including Mr. Dempsey that they would complete a full review of the issue and provide a written presentation for the Board. It also should be noted that Mr. Dempsey tendered his resignation and left the Board meeting during the discussion and prior to any vote regarding the board of the Company’s wholly-owned subsidiary, Vaso Diagnostics, Inc. d/b/a Vaso Healthcare. His decision to resign and remove himself from the Board and in all other positions with the Company was made at a time that alternate proposals, including maintaining a subsidiary board with Mr. Dempsey remaining as chairman, were being considered. By letter dated February 1, 2012, Mr. Dempsey provided his comments on the information disclosed."

    Sentiment: Strong Buy

  • 33% drop since then, but wth, the company's successful, and this stock might gain 10,000% one of these days. FWIW, the Dow fell only 13% on 10/28/1929, and only an additional 12% on 10/29/1929. A very important American [who later did great things behind the scenes to save this great nation] was age 40 when that all went down.

    Sentiment: Strong Buy

  • tfitz71 by tfitz71 Feb 16, 2015 9:19 PM Flag

    Wondering if there's anything new about this:
    WESTBURY, N.Y.–(BUSINESS WIRE) October 7, 2014 – Vasomedical, Inc. (“Vasomedical”) (OTCQB: VASO), a diversified medical technology company specializing in the design, manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products, today announced its engagement of a full service broker dealer to sponsor Vasomedical’s stock for quotation on the OTC Bulletin Board (“OTCBB”). The OTCBB is an electronic quotation system that displays realtime quotes, last-sales price. Volume information for many over the counter (“OTC”) securities that aren't listed on the Nasdaq Stock Market or a national securities exchange. Currently, the Company’s stock is quoted on OTC Link (previously, “Pink Sheets”) operated by OTC Markets Group, Inc. By listing onto the OTCBB, the company believes that its shareholders may potentially benefit by, among other things, additional exposure to the investment community,

    Sentiment: Strong Buy

  • Reply to

    Diabetes Management

    by tfitz71 Feb 13, 2015 5:02 PM
    tfitz71 tfitz71 Feb 13, 2015 6:55 PM Flag

    Google it:
    "Monthly miracles: reversing ischemic heart damage with multiple chelations and EECP."

    Sentiment: Strong Buy

  • Reply to

    Interferons

    by tfitz71 Feb 13, 2015 5:25 PM
    tfitz71 tfitz71 Feb 13, 2015 5:29 PM Flag

    "Mr. Srybnik is a lifetime entrepreneur and industrialist in many industries including aerospace and defense, biotechnology and medical equipment, machinery and machine tools, etc. Among many of his contributions to the country are the service on the war production board during the second world war; the first underground missile base built by his company, Portland Industry in Bangor, Maine, for the United States military; the manufacture of first advanced dosimeter (radiation detection device) in the Dosimeter Corporation; as well as the first production of interferon by his company, Life Sciences."

    Sentiment: Strong Buy

  • tfitz71 by tfitz71 Feb 13, 2015 5:25 PM Flag

    "Commercially available interferons are human interferons manufactured using recombinant DNA technology. The mechanism of action of interferon is complex and is not well understood. Interferons modulate the response of the immune system to viruses, bacteria, cancer, and other foreign substances that invade the body. Interferons do not directly kill viral or cancerous cells; they boost the immune system response and reduce the growth of cancer cells by regulating the action of several genes that control the secretion of numerous cellular proteins that affect growth."

    Sentiment: Strong Buy

  • Reply to

    Diabetes Management

    by tfitz71 Feb 13, 2015 5:02 PM
    tfitz71 tfitz71 Feb 13, 2015 5:16 PM Flag

    As reported by Global Cardio Care, Inc.:
    "EECP causes regeneration of pancreatic tissue to produce insulin for people with diabetes."

    Sentiment: Strong Buy

  • MED Device Online:
    "Recently published clinical studies demonstrated that EECP Therapy is effective in managing glycemic levels and controlling abnormal glucose tolerance in patients with type-2 diabetes. This has increased interest in the effectiveness of EECP Therapy to benefit this patient population."

    Sentiment: Strong Buy

  • Reply to

    GE

    by tfitz71 Jan 6, 2015 4:17 PM
    tfitz71 tfitz71 Feb 13, 2015 11:28 AM Flag

    GE's pps going up, up and away.

    Sentiment: Strong Buy

  • Reply to

    Vasomedical website under construction

    by resellerguy Feb 4, 2015 8:32 AM
    tfitz71 tfitz71 Feb 5, 2015 1:32 PM Flag

    I especially like this part of Vasomedical's announcement:
    "There are treatment centers in the Kingdom of Saudi Arabia, the United Arab Emirates, Egypt, Jordan, the Sudan, Bahrain, Oman and Israel. Many physicians in the region are familiar with the clinical benefits of the therapy and are very interested in bringing the technology to their local hospitals and clinics."

    Sentiment: Strong Buy

  • Reply to

    The British Journal of Cardiology June 2104

    by tfitz71 Jan 25, 2015 6:46 PM
    tfitz71 tfitz71 Jan 25, 2015 6:53 PM Flag

    Even bashers will be asking their doctors for EECP referrals.

    Sentiment: Strong Buy

  • Reply to

    The British Journal of Cardiology June 2104

    by tfitz71 Jan 25, 2015 6:46 PM
    tfitz71 tfitz71 Jan 25, 2015 6:50 PM Flag

    "Correspondence: is it time for a re-assessment of EECP in the UK?"

  • "The effects of EECP treatment on the left heart and coronary circulation are identical to those of the IABP. Both reduce afterload and myocardial oxygen demand. EECP also augments arterial blood flow to other organs such as the brain, kidneys and skin and, by enhancing venous return to the right heart, increases both preload and cardiac output." The British Journal og Cardiology June 2014

    Sentiment: Strong Buy

  • Reply to

    VSK joint venture

    by resellerguy Jan 25, 2015 11:07 AM
    tfitz71 tfitz71 Jan 25, 2015 6:21 PM Flag

    You have to like their state-of-the-art technology. This is bound to translate into exponentially increased patient referrals.

    Sentiment: Strong Buy

  • tfitz71 by tfitz71 Jan 23, 2015 3:04 PM Flag

    How many shares of this are out?

  • Reply to

    GE

    by tfitz71 Jan 6, 2015 4:17 PM
    tfitz71 tfitz71 Jan 23, 2015 2:00 PM Flag

    GE continues to make it its business to be on the forefront of technology. IMHO, playing their stock short takes incredible timing and temerity. Some shorts surely make money on it, but many surely don't.

    Sentiment: Strong Buy

  • Was just reading that patients with peripheral vascular disease experience a marked improvement in their circulation in response to EECP. Such patients tend to do best when they undergo more than the typical 35 hour-long sessions.

    Sentiment: Strong Buy

  • Reply to

    Renewal

    by tfitz71 Jan 13, 2015 4:34 PM
    tfitz71 tfitz71 Jan 13, 2015 4:58 PM Flag

    Columbus wanted to (and thought he was) sailing to India in 1492, and very bright minds from India continue to dazzle the world today. They should have their releases edited by skilled American writers, though.

    Sentiment: Strong Buy

FONR
13.13-0.21(-1.57%)Mar 2 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.